Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome

Trial Profile

Double-blind, Placebo Controlled Trial Comparing Neomycin to Rifaximin Plus Neomycin in the Treatment of Methane Positive Subjects With Constipation-predominant Irritable Bowel Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2015

At a glance

  • Drugs Rifaximin (Primary) ; Neomycin
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Aug 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
    • 01 May 2014 Primary endpoint 'Symptom-severity' has been met according to results published in Digestive Diseases and Sciences.
    • 01 May 2014 Planned number of patients changed from 89 to 88 according to Digestive Diseases and Sciences.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top